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Abstract: The tumor suppressor breast cancer 1, early onset (BRCA1) plays an important role in maintaining the genome integrity,
actively participating in DNA repair via homologous recombination. The level of functional final BRCA1 protein is precisely regulated
in cells. Epigenetic regulation of BRCA1 gene expression is one of the most important mechanisms for BRCA1 level fine-tuning. In this
review the main epigenetic mechanisms of BRCA1 expression regulation are presented, including DNA methylation, histone covalent
modifications, and regulation with transcription factors. Another important function of BRCA1 emerging in recent years is its role in
the regulation of breast cancer stem cell development. Moreover, based on its multiple functions, BRCA1 is also arising as a powerful
biomarker. In particular, it could be used as a prognostic marker of the course of the disease and as a predictive marker of the efficiency
of platinum-based chemotherapy.
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1. Introduction
Breast cancer 1, early onset (BRCA1) is a tumor suppressor.
The BRCA1 protein has a molecular weight of 220 kDa
(Clark et al., 2012) and is coded with the 85-kb BRCA1 gene
located on chromosome 17q (Barker et al., 1996; Tan-Wong
et al., 2008). Mutations in the BRCA1 gene induce the early
onset of hereditary forms of breast cancer (BC) and ovarian
cancer (OC). At the molecular level mutations in the BRCA1
gene lead to the synthesis BRCA1 protein with compromised
function in homologous recombination-dependent DNA
repair. Homologous recombination-dependent DNA repair
is the main function of BRCA1 and its failure leads to
chromosomal instability and further on to the development of
oncologic diseases (Moynahan et al., 1999). Multiple proteins
are involved in BRCA1 functioning, altogether forming the
BRCA1 tumor suppressor network (Jiang and Greenberg,
2015).
The development of sporadic BC and OC due to the
inhibition of BRCA1 function could be the result, on one
hand, of BRCA1 gene mutation accumulation leading to
the formation of nonfunctional protein product, and on
the other hand, of more frequent epigenetic inhibition of
BRCA1 expression. The latter event could be caused by DNA
methylation in the promoter region of the BRCA1 gene as well
as by covalent modifications of nucleosome histone proteins
in the promoter and coding regions of the BRCA1 gene.
* Correspondence: labmedchem@mail.ru

Recent reports also point to the important role of
BRCA1 in cancer stem cell development, and particularly
BC stem cell development.
Due to the fact that the inhibition of BRCA1 function
is related to the development of oncologic diseases, in
particular BC and OC, and in some cases lung, pancreatic,
gastric, and head and neck cancers, recent studies
demonstrated the prognostic and predictive value of
BRCA1 expression at the protein level for the course of the
disease and sensitivity to platinum-based chemotherapy.
In this review articles cited recently in the Pubmed system
are analyzed.
2. BRCA1 protein structure and its role in homologous
recombination-dependent DNA repair
BRCA1 functioning as a tumor suppressor is mainly due to
its participation in genome stability control that depends
on its interaction with multiple associated proteins. The
domain structure of the BRCA1 protein with its associated
partners is presented in Figure 1. This figure is based on
multiple articles and comprehensive reviews (Weberpals et
al., 2008; Clark et al., 2012; Brosh and Cantor, 2014; Jiang
and Greenberg, 2015) that describes BRCA1 structure and
functions. Detailed description of the BRCA1 domains,
their functions, and associated proteins/protein complexes
are presented in the Table.
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Figure 1. Domain structure of tumor suppressor BRCA1; the RING domain, exon 11 with two nuclear localization signals
(NLS), coiled-coil domain, and two BRCT domains are indicated. The main interacting proteins are shown below the
corresponding binding regions and include BARD1, Rad50, Rad51, PALB2, BRCA2, BACH1 (FANCJ), Abraxas, and CtIP
(see text and Table for more details).

Table. Proteins associated with different domains of the BRCA1 protein.
Domain name

Domain function and
characteristics

Protein names

References

RING

E3 Ubiquitin ligase

BARD1

(Wu et al., 1996)

Exon 11

Homologous recombination;
Tumor suppression;
Checkpoint function;
Nuclear localization

Rad50, Rad51, Rb, c-Myc

(Scully et al., 1997; Wang et al., 1998;
Aprelikova et al., 1999; Zhong et al.,
1999)

Coiled-coil
domain

ATM target;
Checkpoint function

PALB2, BRCA2

(Sy et al., 2009)

Abraxas, RAP80, MERIT40, BRCC45,
BRCC36

(Kim et al., 2007; Liu et al., 2007; Wang
et al., 2007)

CtIP, Mre11-Rad50-Nbs1 (MRN)

(Yu and Chen, 2004)

BRCT

Phosphoprotein binding;
BACH1 (BRIP1, FANCJ), TopBP1, BLM (Manke et al., 2003; Yu et al., 2003)
Double-strand break response

BRCA1 consists of several domains (Figure 1, Table)
that include in the N-terminus the RING domain,
which binds to BARD1 (Wu et al., 1996). The BARD1
protein participates in most BRCA1 functions and has
similar overall structure consisting of a RING domain,
two nuclear localization signals (NLS), and two BRCT
domains. The BRCA1 RING domain is followed by exon
11, which does not possess defined structural domains,
although it contains two NLS and binding sites for Rad51
and Rad50, which play an important role in DNA double
strand break (DSB) repair (Scully et al., 1997; Zhong et
al., 1999). Exon 11 contains also binding sites for tumor
suppressor Rb (Aprelikova et al., 1999) and transcriptional
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factor c-Myc with strong oncogenic activities (Wang
et al., 1998). Downstream from exon 11 and partially
overlapping it, there is the coiled-coil domain that is
involved in the binding of another tumor suppressor,
BRCA2, through PALB2 (Sy et al., 2009). This region is
also a target of ATM and ATR checkpoint kinases. Finally,
at the C-terminus of the BRCA1 protein two BRCT
domains are located that present phosphoprotein binding
modules (Leung and Glover, 2011). BRCA1 tandem BRCT
domains could interact with the three mutually exclusive
protein complexes, each of which participates in the
DNA DSB repair pathway, namely the Abraxas/RAP80containing complex (Kim et al., 2007; Liu et al., 2007;
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Wang et al., 2007), BACH1-containing complex (Manke
et al., 2003; Yu et al., 2003), and CtIP-containing complex
(Yu and Chen, 2004). The protein composition of each of
these complexes is presented in the Table. BRCA1 plays
an important role in the repair of DNA DSB through the
error-free homologous recombination. In this regard it is
important to mention that proper functioning of BRCA1
in homologous recombination is strongly correlated with
its role in BC suppression (Chen et al., 1999; Moynahan
et al., 2001; Walsh and King, 2007; Hu et al., 2011).
One of the most striking examples of the inhibition of
BRCA1 function leading to chromosome instability is the
appearance of radial chromosomal structures (Silver et al.,
2007; Hu et al., 2011).
3. Mechanisms of inhibition of BRCA1-dependent
homologous recombination
3.1. BRCA1 mutations leading to the inhibition of DNA
repair
Mutations in the BRCA1 gene predispose to the
development of basal-like BCs with high metastasis and
poor prognosis (Bai et al., 2014). In general, the causes of
5%–10% of BCs and OCs are hereditary mutations in the
BRCA1 gene, while 90%–95% of BCs and OCs are sporadic
forms of these diseases (Wong-Brown et al., 2015). In 20%
of a subtype of BC, triple negative BC, the patients carry
germline mutations in the BRCA1 gene (Weberpals et al.,
2008). However, not all, but only certain, clinically relevant
mutations in the BRCA1 gene lead to the development
of BC and OC. Moreover, in contrast with other tumor
suppressor genes, somatic mutations in the BRCA1 gene
are quite rare and are not the main cause of sporadic BC
and OC development. For example, in the case of sporadic
epithelial OC, the BRCA1 gene mutations are detected in
9% of cases (Hosking et al., 1995). These facts suggest that
at least some part of sporadic forms of BC and OC is due to
the epigenetic inhibition of BRCA1 expression that leads
to reduced levels of BRCA1 protein product, and therefore
to insufficient BRCA1 protein function in homologous
recombination, and finally to the development of cancer.
3.2. Epigenetic mechanisms of BRCA1 expression
regulation
In this section data are presented demonstrating
epigenetic inhibition of BRCA1 expression due to
covalent modification of DNA and chromatin histone
proteins as well as deregulation of BRCA1 expression with
transcription factors that altogether are involved in the
development of sporadic forms of BC and OC.
One of the important mechanisms of BRCA1
expression inhibition is the methylation of CpG islands
in the promoter and coding regions of the BRCA1 gene.
Increases in CpG island methylation in the BRCA1 gene
were repeatedly demonstrated in BC and OC tissue samples

(Esteller et al., 2000; Rice et al., 2000; Esteller et al., 2001;
Turner et al., 2007; Wong et al., 2011). DNA methylation
is a stable modification that is maintained during mitotic
divisions of cells (Jones and Liang, 2009; Sharma et al.,
2011). Inhibition of BRCA1 gene expression as well as of
a series of other tumor suppressor genes induced by DNA
methylation could be reversed with directed binding of
demethylating enzymes to target genes (De Groote et al.,
2012; Chen et al., 2014).
Another important mechanism of BRCA1 expression
regulation is the binding of transcription factors to the
BRCA1 gene promoter, which could lead to the inhibition
or activation of this tumor suppressor expression in BC
and OC (Figure 2). In human BRCA1 locus the BRCA1
gene start site is located close (218 bp) to the start site of the
NBR2 gene and these two genes are transcribed in opposite
directions (Dimitrov et al., 2001; McCoy et al., 2003a;
Mueller and Roskelley 2003; Figure 2A). The inhibition
of BRCA1 expression could be due either to a decrease in
binding of the activator or an increase in binding of the
repressor. It was demonstrated that, on one hand, in OC
there is a decrease in binding of activating transcription
factor GABP-a/b with the BRCA1 gene promoter, leading
to the inhibition BRCA1 expression (McCoy et al., 2003a;
McCoy et al., 2003b; Figure 2B), while on the other hand,
transcription factor ETS-2 forms repressive complex with
the chromatin remodeling factor of the SWI/SNF family,
Brg-1, that upon binding with BRCA1 gene inhibits its
expression (Baker et al., 2003; Figure 2B), obviously
competing with GABP-a/b binding to the RIBS element.
The inhibitor of differentiation 4 (ID4) also functions as
the repressor of BRCA1 expression (McCoy et al., 2003a;
Figure 2B). The cyclic-AMP response element binding
protein (CREB) positively regulates BRCA1 promoter
binding to the cyclic-AMP response element located
in the positive regulatory region (DiNardo et al., 2001;
McCoy et al., 2003a; Mueller and Roskelley 2003; Figure
2B). Another important regulatory element in the BRCA1
promoter is the E2F binding site, which interacts either
with the repressors of BRCA1 expression, E2F6 and p53,
or the activator of BRCA1 expression, E2F1 (MacLachlan
et al., 2000; Oberley et al., 2003; Figure 2B). Binding
of 53BP1 to the site adjacent to the E2F element also
positively regulates BRCA1 expression (Rauch et al., 2005;
Figure 2B). Moreover, SET1A, an H3K4 methyltransferase,
and BAT3, a cochaperone recruiter, together with an
insulator DNA-binding protein, BORIS, bind to the
upstream promoter region of the BRCA1 gene and activate
it (Nguyen et al., 2008). Data obtained in the mentioned
studies point out to the precise mechanism of action of
transcription factors that include epigenetic modification
of nucleosomal histones and chromatin remodeling during
BRCA1 synthesis inhibition in BC and OC.
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Scheme of the BRCA1 promoter
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Figure 2. Scheme of the BRCA1 promoter: A) General scheme of the BRCA1 gene with the adjacent NRB2 gene
transcribed in the opposite direction. The minimal bidirectional promoter region is indicated. The distance between
the start sites of BRCA1 and NBR2 genes comprises 218 bp; B) The scheme of the proximal BRCA1 promoter is
presented in which regulatory sequences and binding proteins that function either as positive regulatory factors
or negative regulatory factors are indicated. The BRCA1 gene promoter is positively regulated with transcriptional
factors GABPa/b, CREB, 53BP1, and E2F1, and negatively regulated with transcriptional factors ETS-2/Brg-1, ID4,
E2F6, and p53 (see text for more details).

In BC and OC BRCA1 gene expression regulation
could take place also at the level of covalent modifications
of histones, a structural part of the nucleosome which,
in turn, is a basic unit of chromatin (Lee and Lee,
2012). In Figure 3 the key histone H3/4 and H2A/H2B
covalent modifications are depicted including acetylation,
methylation, phosphorylation, and ubiquitination.
Acetylation,
methylation,
and
phosphorylation
are ubiquitous modifications characteristic for the
N-terminal protrusions of histones H3, H4, H2A, and
H2B. Ubiquitination is a more common modification
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of the C-terminal protrusions of histones H2A and
H2B. However, there is a limited number of studies
analyzing particular histone modifications at the BRCA1
gene promoter and coding region that may be due to
complicated combinatorial nature of histone modifications,
usually revealed with chromatin immunoprecipitation
(ChIP) and immunoblotting techniques. Some research
works address the total acetylated/deacetylated state of
chromatin in tumor cells in relation with BRCA1 function.
It was demonstrated that in chemoresistant head and neck
squamous cell carcinoma, tumor cells had reduced nuclear
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Figure 3. Covalent modifications of histones H3/4 and H2A/2B. The main modifications
of histones H3/4 and H2A/H2B are presented, including acetylation, methylation,
phosphorylation, and ubiquitination. Acetylation, methylation, and phosphorylation are
ubiquitous modifications characteristic for the N-terminal protrusions of histones H3, H4,
H2A, and H2B. Ubiquitination is a more common modification of the C-terminal protrusions
of histones H2A and H2B.

size, cytoplasmic localization of BRCA1, reduced levels
of BRCA1 protein, and deacetylated histone H3 (Lys 9),
corresponding to chromatin condensation (Almeida et al,
2014). Therefore, the observed chromatin condensation
results in the inhibition of BRCA1 gene transcription and
also could prevent the intercalation of cisplatin in the
DNA structure and the access of BRCA1 to sites of DNA
damage.
In addition to the several mechanisms of BRCA1
expression inhibition described earlier in this review, the
loss of heterozygosity (LOH) also could lead to complete

disappearance of tumor suppressor BRCA1 in cells (Russel
et al., 2000).
Moreover, recently it was demonstrated that the BRCA1
gene could be amplified in oral squamous cell carcinoma
(Ribeiro et al., 2014). BRCA1 gene amplification could
lead to aberrant increase of BRCA1 protein synthesis,
therefore changing BRCA1 functioning in homologous
recombination.
It is also important to note that the 85-kb BRCA1 gene
located on chromosome 17q forms loops between the
promoter, intron, and terminator regions. Loop formation
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between these regions is dynamically regulated depending
on the transcriptional status of the BRCA1 gene (TanWong et al., 2008).
Not only a decrease in BRCA1 protein expression, but
also an exaggerated increase in BRCA1 protein levels could
lead to chromosomal instability and cancer development
(Hu et al., 2011). Therefore, endogenous native level of
BRCA1 expression is necessary for the maintenance of
proper BRCA1 functioning in homologous recombination
in order to achieve chromosomal stability and cellular
homeostasis.
4. Role of BRCA1 in BC stem cells (BCSCs) development
Recently several reports were published demonstrating
that BRCA1 has an important role in the regulation of
growth, proliferation, and differentiation of BCSCs, which
are often referred to as BC stem-like cells and mammary
luminal stem cells (MLSCs) (Bai et al., 2014; Gilabert et al.,
2014; Pickholtz et al., 2014). On one hand, it was known
that the germline mutation in BRCA1 causes luminalto-basal mammary tumor transformation. On the other
hand, the deletion of p18 (Ink4c)(p18) inhibits CDK4 and
CDK6, inactivates the RB pathway, and stimulates MLSC
proliferation, finally leading to spontaneous luminal tumor
development. In a study by Bai et al. (2014) it was shown
that the disruption of BRCA1 by germline or epitheliumspecific mutation on p18-deficient background activates
the epithelial-to-mesenchymal transition (EMT) in
mice and induces dedifferentiation of MLSCs, which
is associated with the expansion of basal and cancer
stem cells and the formation of basal-like tumors. The
authors revealed the molecular mechanisms of BRCA1
function in the inhibition of EMT. BRCA1 inhibits the
EMT in mammary tumor cells via binding to the TWIST
promoter and suppressing its activity. The increase in
TWIST expression and EMT correlated with the decrease
in BRCA1 expression. Taken together, for the first time
the authors presented genetic evidences that BRCA1
suppressed TWIST, EMT, and MLSC dedifferentiation and
repressed the expansion of basal stem cells and basal-like
tumors during BC-genesis.
Another molecular mechanism of BRCA1-dependent
growth inhibition of BC stem-like cells and BC cells was
described by Pickholtz et al. (2014). In this work it was
demonstrated that BRCA1 in the presence of vitamin D
binds to vitamin D responsive elements at the p21waf1
promoter, inducing the acetylation of histone H3 and H4
at this promoter that leads further to increased expression
of p21waf1 followed by growth inhibition of both BC
stem-like cells and BC cells.
In one more study (Gilabert et al., 2014) it was
demonstrated that aldehyde dehydrogenase (ALDH)
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containing cells are enriched in BCSCs. In ALDH+ BCSCs
the overexpression of poly(ADP-ribose) polymerase 1
(PARP1) contributed to the resistance to PARP inhibitors
such as olaparib. Particularly high expression of PARP1
was found in ALDH+ cells from BRCA1-mutated
HCC1937 and these cells demonstrated resistance to the
specific PARP1 inhibitor, olaparib.
5. BRCA1 is a prognostic marker of disease course and
a predictive marker of platinum-based chemotherapy
efficiency
In recent years it has become clear that BRCA1 could serve
as a biomarker for several types of cancer. In order for a
particular molecule to be a biomarker, it should have a
defined biological function, there should be method(s) to
measure its quantity, and patient cohorts of reasonable size
should be available to study its prognostic and predictive
value. BRCA1 protein and BRCA1 mRNA fit well into this
definition as BRCA1 protein and mRNA expression levels
are prognostic factors of disease course (Wilson et al.,
1999; Wang et al., 2004; Al-Mulla et al., 2005; Thrall et al.,
2006; Tulchin et al., 2013; Shilpa et al., 2014). Moreover,
patients with BC and especially OC are the subjects of
neoadjuvant and adjuvant platinum-based chemotherapy.
It is worth to note that patients with altered BRCA1

Chemotherapeutic platinum-containing compounds
Cisplatin

Carboplatin

Oxaliplatin

Figure 4. Platinum-based chemotherapeutic compounds. Three
commonly used platinum-containing compounds, cisplatin,
carboplatin, oxaliplatin, are presented. They are broadly used
in chemotherapeutic treatment of patients with oncological
diseases.
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expression usually are more sensitive to chemotherapeutic
platinum-containing compounds including cisplatin,
carboplatin, and oxaliplatin (Quinn et al., 2007; Byrski et
al., 2009; Silver et al., 2010; Carser et al., 2011; Weberpals
et al., 2011; Byrski et al., 2014). The structure of these
commonly used platinum-containing compounds is
presented in Figure 4. These compounds could easily
disturb the DNA structure, intercalating between the bases.
Carboplatin and oxaliplatin are especially efficient due to
the presence of heterocycles in their structure. Diminished
BRCA1 protein levels could lead to decreased restoration
of the native DNA structure due to the lack of BRCA1dependent activity that removes the DNA cross-linked
adducts. This would lead to increased deleterious effects
of platinum-based compounds towards cancer cells, and
therefore would increase the efficiency of platinum-based
chemotherapy.
Many recent studies demonstrated that BRCA1
expression on mRNA and the protein level could be
a powerful prognostic marker of disease course and a

predictive marker of platinum-based chemotherapy
efficiency.
6. Conclusion
The review of multiple data on the epigenetic mechanisms of
tumor suppressor BRCA1 expression regulation sheds light
on its fine-tuning function in homologous recombination
and clarifies some aspects of the sophisticated mechanisms
of cancer development, especially involving cancer stem
cells. The multifaceted regulation of BRCA1 expression
includes multiple mechanisms, among which are
epigenetic regulation on the level of DNA and histone
covalent modifications, regulation with transcriptional
factors, LOH, and potentially gene amplification.
Moreover, based on its multiple and important
functions in cells and on developing methods for its
detection, BRCA1 is arising as a powerful prognostic
marker of the course of several cancers, in particular BC
and OC, and as a predictive marker of the efficiency of
platinum-based chemotherapy for these diseases.
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